| 2.16 0.1 (4.85%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.66 | 1-year : | 3.11 |
| Resists | First : | 2.27 | Second : | 2.66 |
| Pivot price | 1.72  |
|||
| Supports | First : | 1.69 | Second : | 1.33 |
| MAs | MA(5) : | 2.03 |
MA(20) : | 1.72 |
| MA(100) : | 2.76  |
MA(250) : | 14.02 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.1 |
D(3) : | 75 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 250 | Low : | 1.33 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NCNA ] has closed below upper band by 10.6%. Bollinger Bands are 28.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.2 - 2.21 | 2.21 - 2.22 |
| Low: | 2.05 - 2.06 | 2.06 - 2.07 |
| Close: | 2.14 - 2.16 | 2.16 - 2.17 |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Tue, 14 Apr 2026
+5.10% for NuCana stock as overbought conditions emerge - Traders Union
Mon, 13 Apr 2026
+8.63% for NuCana stock as fresh highs prompt overbought signals - Traders Union
Fri, 10 Apr 2026
NCNA Should I Buy - Intellectia AI
Thu, 09 Apr 2026
NCNA News | NUCANA PLC-ADR (NASDAQ:NCNA) - ChartMill
Wed, 01 Apr 2026
NuCana (NASDAQ: NCNA) director discloses options and share stakes - Stock Titan
Tue, 24 Mar 2026
NuCana (NCNA) executive details large option grants in Form 3 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 20,810 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 160 (K) |
| Shares Short P.Month | 188 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.4 % |
| Return on Equity (ttm) | -193.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|